Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

Nature recognized as key component of lifestyle medicine and health

5

Oct 2026

Nature recognized as key component of lifestyle medicine and health

The American College of Lifestyle Medicine (ACLM) today welcomed a resolution adopted by the Association of Fish and Wildlife Agencies (AFWA) that recognizes nature's role in supporting human health and calls for greater collaboration among the conservation, healthcare and research communities.

Phase III trial tests MRD-guided treatment for patients with ER-positive/HER2-negative breast cancer

5

Oct 2026

Phase III trial tests MRD-guided treatment for patients with ER-positive/HER2-negative breast cancer

Alliance Foundation Trials, LLC (AFT), a national leader in conducting innovative, practice-changing cancer clinical trials, and Natera, Inc., a global leader in cell-free DNA and precision medicine, today announced the launch of AFT-70 NAVIGATE, a randomized phase III trial evaluating a novel molecular residual disease (MRD)-guided treatment strategy for patients with intermediate and high-risk ER-positive/HER2-negative early breast cancer.

Health evidence favors permanent standard time, Canadian analysis finds

5

Oct 2026

Health evidence favors permanent standard time, Canadian analysis finds

Several Canadian jurisdictions are moving toward ending the twice-yearly clock change, but a new analysis published in CMAJ (Canadian Medical Association Journal) https://www.cmaj.ca/lookup/doi/10.1503/cmaj.261089 argues that eliminating the clock change is only half the decision: governments must also decide whether to adopt permanent standard time or permanent daylight saving time.

New BCR analysis method tracks immune recovery after stem cell transplantation

5

Oct 2026

New BCR analysis method tracks immune recovery after stem cell transplantation

A research team led by Associate Professor Yohei Funakoshi, Associate Professor Kimikazu Yakushijin, and Professor Hironobu Minami of the Division of Medical Oncology/Hematology at Kobe University Hospital, together with Associate Professor Goh Ohji of the Division of Infectious Disease Therapeutics and Takaji Matsutani of Anymics Inc., has developed the pGen-SHM plot.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.